Replies to post #27076 on The Rising Influence of Rising Affluence

[santafe2]

These are excellent devices for anyone managing insulin dosing or for athletes in training. The downside for many is cost; over $10 a day, less with insurance, (Blue Cross pays half). Also, (locally at least), they're not approved for use in hospitals. One could argue that this is because hospitals would no longer be able to charge to poke their insulin deficient patients 10 times a day.

The Libre also requires the wearer to purposefully interact with the device and their smartphone. Not a big deal for most but for the elderly who may live alone or have issues with technology and/or mental capacity, it will prove to be less useful. A Libre which automatically takes readings will greatly expand use in this area.

[DewDiligence]

FDA enables_integration_of FreeStyle Libre with automated insulin delivery systems:

https://finance.yahoo.com/news/u-fda-clears-abbotts-freestyle-120000948.html

Abbott today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.

…AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors.

Abbott is working with leading insulin pump manufacturers to integrate their systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors as soon as possible. The company is partnering with Insulet and Tandem for future integrations in multiple countries, including the U.S. Outside the U.S., Abbott's FreeStyle Libre 3 sensor is already authorized to work with the mylife Loop solution from Ypsomed and CamDiab in Germany, with additional launches in the UK, Switzerland and the Netherlands planned for the first half of this year.

FreeStyle Libre, already the biggest-selling medical device from any company, is projected to reach $10B(!) in annual sales during the next five yeaqrs, according to ABT’s statement at the JPM conference in January 2023 (#msg-170908065). Current annual sales are more than $4B.

[DewDiligence]

ABT partners with ADA to assist type-2 diabetics in dietary planning:

https://finance.yahoo.com/news/american-diabetes-association-abbott-collaborate-181500748.html

ABT’s Freestyle Libre continuous glucose monitor, which has annualized sales of ~$5B (#msg-171723150) and is expected to reach $10B by 2028 (#msg-170908065), makes ABT a bona fide T2D investment play.